Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the appointment of Saira Ramasastry to its board of directors and audit committee. Ramasastry brings over 20 years of financial leadership, including her experience at Merrill Lynch & Company. CEO Chris Peetz emphasized her strategic experience as crucial for expanding the company’s reach and enhancing its rare disease pipeline. Mirum develops therapies like LIVMARLI® for liver diseases and has ongoing clinical trials for innovative treatments, showing commitment to advancing care for patients.

Mirum Pharmaceuticals has acquired Satiogen Pharmaceuticals, consolidating its licensing obligations for LIVMARLI® and volixibat. This strategic move is anticipated to improve cash flow and reduce royalty payments to high single digits. The total transaction value includes 841,792 shares of common stock and approximately $2.8 million in cash. CEO Chris Peetz highlighted the acquisition as a vital step towards enhancing the company’s pipeline and commercial programs, especially for rare liver diseases.

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced its participation in key virtual investor conferences. The H.C. Wainwright Global Investment Conference is set for May 24, 2022, with a fireside chat starting at 8:30 a.m. ET. Following this, Mirum will present at the Jefferies Healthcare Conference on June 9, 2022, from 9:00-9:30 a.m. ET. The company focuses on treatments for rare liver diseases, with its approved drug LIVMARLI for Alagille syndrome and investigational treatments for various liver diseases.

Mirum Pharmaceuticals, Inc. (MIRM) has granted inducement awards to 18 new employees, comprising 178,000 non-qualified stock options and 52,677 restricted stock units (RSUs) as of May 10, 2022. The stock options have an exercise price of $22.55, corresponding to Mirum's closing price on that date, and will vest over four years. The RSUs will vest over three years. These awards are part of Mirum's 2020 Inducement Plan and adhere to Nasdaq Listing Rule 5635(c)(4). Mirum focuses on rare diseases and is advancing its clinical pipeline for liver diseases.

Mirum Pharmaceuticals reported a total revenue of $12.9 million for Q1 2022, with net product revenue from LIVMARLI® at $10.9 million. This marks significant growth compared to the previous year's figures. Operating expenses decreased to $45.6 million from $47.6 million in Q1 2021. Despite a net loss of $36.6 million (or $1.17 per share), it was an improvement from last year’s loss of $50.5 million. The company anticipates key clinical trial data and regulatory approvals in late 2022, enhancing prospects for future revenue growth.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report its first quarter financial results on May 5, 2022.

A conference call will be held at 8:30 a.m. ET to discuss the company's progress and priorities for 2022. Investors can join via U.S. toll-free dial-in 844-200-6205 or access the call via webcast. Mirum focuses on rare diseases, with its approved medication LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is also evaluating investigational treatments for various liver diseases and has submitted a Marketing Authorization Application to the European Medicines Agency.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced on April 8, 2022, that its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The awards comprise 25,500 stock options priced at $27.46 each and 12,650 RSUs. The options will vest over four years, while the RSUs will vest over three years. Mirum focuses on developing treatments for rare diseases, with its marketed drug LIVMARLI® approved for cholestatic pruritus in Alagille syndrome patients. The company also has ongoing clinical trials for additional treatments.

On March 10, 2022, Mirum Pharmaceuticals (NASDAQ: MIRM) granted inducement awards to two new employees, consisting of non-qualified stock options for 16,350 shares and 8,150 restricted stock units (RSUs). The stock options have an exercise price of $21.91, equivalent to the company's closing price on the grant date, and will vest over four years. The RSUs will vest over three years. These grants are part of Mirum's 2020 Inducement Plan and comply with Nasdaq regulations.

Mirum Pharmaceuticals reported a strong start for its product LIVMARLI, generating $3.1 million in net revenue in Q4 2021. Total revenue for 2021 reached $19.1 million. The company anticipates at least $8.0 million in net sales for LIVMARLI in Q1 2022. Major highlights include the sale of a Rare Pediatric Disease Priority Review Voucher for $110 million and a new patent granted for LIVMARLI, providing protection until 2040. The company reported a Q4 net income of $57.5 million, but a net loss for the year of $84 million.